Clinical and Experimental Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
GPI, Società per Azioni (SpA), 38123 Trento, Italy.
Genes (Basel). 2019 Apr 4;10(4):276. doi: 10.3390/genes10040276.
Pharmacogenetic (PGx) guidelines for the precise dosing and selection of drugs remain poorly implemented in current clinical practice. Among the barriers to the implementation process is the lack of clinical decision support system (CDSS) tools to aid health providers in managing PGx information in the clinical context. The present study aimed to describe the first Italian endeavor to develop a PGx CDSS, called FARMAPRICE. FARMAPRICE prototype was conceived for integration of patient molecular data into the clinical prescription process in the Italian Centro di Riferimento Oncologico (CRO)-Aviano Hospital. It was developed through a coordinated partnership between two high-tech companies active in the computerization of the Italian healthcare system. Introducing FARMAPRICE into the clinical setting can aid physicians in prescribing the most efficacious and cost-effective pharmacological therapy available.
药物基因组学(PGx)指导原则在当前的临床实践中仍未能得到很好的实施。在实施过程中的障碍之一是缺乏临床决策支持系统(CDSS)工具,以帮助医疗服务提供者在临床环境中管理 PGx 信息。本研究旨在描述意大利首次开发 PGx CDSS 的努力,称为 FARMAPRICE。FARMAPRICE 原型的设计目的是将患者的分子数据整合到意大利 Centro di Riferimento Oncologico(CRO)-Aviano 医院的临床处方流程中。它是通过两家活跃于意大利医疗保健系统计算机化的高科技公司之间的协调合作开发的。将 FARMAPRICE 引入临床环境可以帮助医生开出最有效和最具成本效益的药物治疗方案。